Table 1.
Patient characteristics
| Characteristic | N (%) |
|---|---|
| Age (years) | |
| ≤ 40 | 23(26.4%) |
| 41–50 | 27(31.1%) |
| > 50 | 37(42.5%) |
| Histologic subtype | |
| No special type | 85(97.7%) |
| lobular | 2(2.3%) |
| Tumor size (cm) | |
| ≤ 0.5 | 1(1.1%) |
| > 0.5, ≤ 1 | 20(23.0%) |
| > 1, ≤ 2 | 66(75.9%) |
| Histologic Grade | |
| 1 | 17(19.6%) |
| 2 | 59(67.8%) |
| 3 | 11(12.6%) |
| Ki67 | |
| ≤ 30% | 16(18.4%) |
| > 30% | 71(81.6%) |
| P53 | |
| Positive | 25(28.7%) |
| Negative | 62(71.3%) |
| Basal-like marker | |
| Positive | 12(13.8%) |
| Negative | 75(86.2%) |
| TILs | |
| ≤ 10% | 65(74.7%) |
| 11–59% | 19(21.8%) |
| ≥ 60% | 3(3.5%) |
| IHC surrogated subtype | |
| Luminal A | 61(32.2%) |
| Luminal B | 26(67.8%) |
| Immune score | |
| Strong | 43(49.4%) |
| Weak | 44(50.6%) |
| Chemotherapy | |
| Yes | 26(29.9%) |
| No | 61(70.1%) |
| Endocrine therapy | |
| Yes | 87(100%) |
| No | 0(0%) |
| Radiotherapy | |
| Yes | 25(28.7%) |
| No | 62(71.3%) |
| Recurrent status | |
| Yes | 26(29.9%) |
| No | 61(70.1%) |
| Distant metastasis | |
| Yes | 15(17.2%) |
| No | 72(82.8%) |
| Living status | |
| Yes | 84(96.6%) |
| No | 3(3.4%) |